DatScan With Prototype Collimator



Status:Completed
Conditions:Parkinsons Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:50 - 75
Updated:5/4/2018
Start Date:June 2015
End Date:September 2017

Use our guide to learn which trials are right for you!

Investigating the Use of Siemens Prototype UHRSZ Collimator for Imaging DatScan SPECT/CT Imaging

A collimator is an accessory to a SPECT/CT scanner. It can be compared to a camera lens or
filter that enhances or improves photos. The prototype collimators are able to magnify target
organs about four times compared to the current collimators. In this study we are validating
a new collimator design, which will allow for quantitative measurement of dopamine receptors
within the brain, not previously performed using a single photon gamma camera.

Previously PET/CT has been used for this measurement but the L-DOPA is not FDA approved and
thus of limited availability. DatScan (I123 ioflupane) is an FDA approved and clinically
indicated biomarker, which has a high binding affinity for presynaptic dopamine transporters
(DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of
Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By
introducing an agent that binds to the dopamine transporters a quantitative measure and
spatial distribution of the transporters can be obtained. The use of SPECT/CT (with the new
validated collimators) and the FDA approved DATScan biomarker would allow for readily
available diagnosis of Parkinson's disease

Inclusion Criteria:

- all patients referred

Exclusion Criteria:

- anyone who wishes to not participate and cannot lay on the table for an additional 30
minutes.
We found this trial at
1
site
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials